: A Randomized, Multinational, Double-Blind, Placebo-Controlled Parallel-Group Design Pilot Study to Estimate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamic Effects of Teriflunomide for 24 Weeks When Added to Treatment with Glatiramer Acetate in Subjects with Multiple Sclerosis, Sanofi-Aventis.